pharmaphorum3d
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer
GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...
pharmaphorum3d
GSK told to pay higher royalties to AZ on Zejula sales
The judgment is from a lawsuit first filed two years ago, in which AZ alleged breach of an agreement between the original developer of Zejula (niraparib) – Tesaro – which was acquired by GSK ...